EMEA-001151-PIP02-17

Key facts

Active substance
  • dapagliflozin
  • metformin (hydrochloride)
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0059/2018
PIP number
EMEA-001151-PIP02-17
Pharmaceutical form(s)
Modified-release tablet
Condition(s) / indication(s)
Treatment of type II diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB (UK)

Tel. +44 1625230700
E-mail: paediatrics@astrazeneca.com

 

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating